Journal profile · Oncology
ONCOLOGY-NEW YORK
ISSN 0890-9091 · UBM Medica Healthcare Publications · United States · Monthly · Founded 1987
ONCOLOGY-NEW YORK: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.53; subscription journal; review 6–12 weeks (community reports); community-reported acceptance: moderate; 35 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
ONCOLOGY-NEW YORK is published by UBM Medica Healthcare Publications and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics and Lymphoma Diagnosis and Treatment, together about 21.9% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
Source: LetPub
Research area (LetPub): Oncology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine8.2%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology7.1%
- Lymphoma Diagnosis and TreatmentMedicine6.6%
- Economic and Financial Impacts of CancerEconomics, Econometrics and Finance6.6%
- Multiple Myeloma Research and TreatmentsMedicine5.5%
- Lung Cancer Treatments and MutationsMedicine5.2%
- CAR-T cell therapy researchMedicine5.2%
- COVID-19 and healthcare impactsMedicine4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.53LetPub ·
- CiteScore 2026-06
- 2.7LetPub ·
- SJR 2026-06
- 0.53LetPub ·
- SNIP 2026-06
- 0.51LetPub ·
- h-index
- 67LetPub ·
- h-index
- 15OpenAlex ·
- i10-index
- 28OpenAlex ·
- 2-year mean citedness
- 0.85OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 0%LetPub ·
Volume
- Articles per year
- 21LetPub ·
Articles by year OpenAlex count · 365 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 21 | 2 | 3 |
| 2025 | 35 | 1 | 34 |
| 2024 | 31 | 5 | 37 |
| 2023 | 52 | 13 | 137 |
| 2022 | 55 | 14 | 293 |
| 2021 | 77 | 14 | 349 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- UBM Medica Healthcare Publications
- Country or region
- United States
- Language
- English
- Frequency
- Monthly
- Founded
- 1987
- ISSN
- 0890-9091
- Official links
- Journal homepage ↗OpenAlex
FAQ
Frequently asked questions about ONCOLOGY-NEW YORK
What CAS zone is ONCOLOGY-NEW YORK in?
In the 2025 upgraded edition of the CAS Journal Ranking, ONCOLOGY-NEW YORK is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of ONCOLOGY-NEW YORK?
The latest impact factor listed by LetPub is 1.53; CiteScore 2.7, h-index 15.
How long does peer review take at ONCOLOGY-NEW YORK?
Authors report an average review time of 6–12 weeks; the community-reported acceptance is “Moderate”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index ONCOLOGY-NEW YORK?
According to LetPub and DOAJ records, ONCOLOGY-NEW YORK is indexed in SCIE and Scopus.
Is ONCOLOGY-NEW YORK open access, and what is the APC?
ONCOLOGY-NEW YORK is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .